Morpholine

Morpholine

SCHEMBL7984701

C1COCCN1.CCOc1cccc(COC(=O)c2ccccc2)c1

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.48
TP53 P04637 2/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
SLC6A2 P23975 1/20 0.47
SLC6A3 Q01959 1/20 0.47
KMT2A Q03164 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
MRGPRX4 Q96LA9 2/20 0.46
PKM P14618 1/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
ALDH1A1 P00352 2/20 0.46
MAPT P10636 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.43
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.43
MAOB P27338 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Morpholine SCHEMBL7985369 0.81 NR1H4 (0.56) SMN1; SMN2TP53NPC1RAB9AKMT2A
Morpholine SCHEMBL7988982 0.78 RAB9A (0.46) SMN1; SMN2TP53NPC1RAB9ANPSR1
SCHEMBL7984700 0.76 KDM4E (0.59) TP53ALDH1A1L3MBTL1
SCHEMBL20830918 0.73 KMT2A (0.67) SMN1; SMN2TP53NPC1RAB9ASLC6A2
SCHEMBL5085785 0.72 KMT2A (0.81) SMN1; SMN2NPC1RAB9ASLC6A2SLC6A3
Morpholine SCHEMBL28263111 0.72 TDP1 (0.45) SMN1; SMN2NPC1RAB9ASLC6A2SLC6A3
SCHEMBL13034129 0.71 ALDH1A1 (0.56) SMN1; SMN2TP53NPC1RAB9AKMT2A
SCHEMBL6670098 0.71 L3MBTL1 (0.58) SMN1; SMN2KMT2ATDP1ALDH1A1L3MBTL1
SCHEMBL6671241 0.71 KMT2A (0.63) SMN1; SMN2NPC1RAB9ASLC6A2SLC6A3
Morpholine SCHEMBL7989270 0.71 PLA2G4B (0.59) SMN1; SMN2TP53NPC1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6310070-B1 FOR TREATING NEPHRITIS, IMPROVING PROTEINURIA DUE TO GLOMERULONEPHRITIS AND PREVENTING AGGRAVATION OF NEPHRITIS JAPAN ENERGY CORPORATION (JP) 2001-10-30 US disclosed
EP-0999211-A1 NOVEL PURINE DERIVATIVES AND MEDICINAL USE THEREOF JAPAN ENERGY CORPORATION (JP) 2000-05-10 EP disclosed